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Treating Asymptomatic
Chemotherapy-Induced
Cardiac Dysfunction
A Chance That Cardiologists
and Oncologists Should Not Miss
We have read the work by Yoon et al. (1) with great interest. The
authors point out that many cancer survivors showing cardiac
dysfunction after oncologic therapy do not receive treatment
consistent with heart failure guidelines, particularly if they are in
the asymptomatic phase of this form of cardiomyopathy. More-
over, they state that it is not clear whether treatment of asymp-
tomatic cardiac dysfunction in cancer patients decreases the risk of
developing symptomatic heart failure and adverse cardiac events
and that no prospective studies have ever evaluated this topic.
However, some stronger and more recent evidence than that
reported by the authors—like the work by Haq et al. (2), dating
back to 1985, in which patients were treated with only digoxin and
diuretics—have been provided with regard to treatment of
chemotherapy-induced left ventricular dysfunction with modern
heart failure therapy. A few years ago, Tallaj et al. (3) reported that
the cardiac prognosis of chemotherapy-induced cardiomyopathy
can be positively affected when patients are treated with
angiotensin-converting enzyme inhibitors and that the addition of
a beta-blocker might further improve the clinical outcome and
reverse left ventricular dysfunction. Moreover, in a recently pub-
lished prospective study, considering a population of 201 patients
with anthracycline-induced cardiomyopathy, we demonstrated
that an early treatment including angiotensin-converting enzyme
inhibitor and beta-blocker, started within 6 months from the end
of chemotherapy, allows for a complete recovery of left ventricular
ejection fraction and positively impacts cardiac outcome (4).
Notably, the clinical benefit was more evident in asymptomatic
patients; indeed, most patients showing a complete recovery from
cardiac dysfunction were either asymptomatic or had a low New
York Heart Association functional class at the time heart failure
therapy was initiated. This suggests that early detection of asymp-
tomatic left ventricular dysfunction or even of subclinical cardio-
toxicity (early increase of troponin I preceding left ventricular
dysfunction) (5) is of paramount importance to successfully treat or
prevent cardiotoxicity. Therefore, monitoring of cardiotoxicity,
exclusively on the basis of symptoms evaluation, might miss the
opportunity to early detect cardiac injury in a still-reversible stage.
Finally, we strongly agree with Yoon et al. (1) that oncologists
and cardiologists should better collaborate in the assessment of
patients receiving potentially cardiotoxic agents, because therapy
decisions involving the same patients might potentially mean
exchanging one fatal disease for another. c*Daniela Cardinale, MD, PhD
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Reply
We greatly appreciate the letter from Dr. Cardinale and colleagues
regarding our recent paper on the care of cancer patients who have
developed treatment-emergent left ventricular dysfunction (1). We
wholeheartedly concur that monitoring of cardiotoxicity by screening
for symptoms of heart failure alone misses the vast majority of
individuals with cardiotoxicity—an observation seen time and time
again in clinical trials (2,3). Assigning nonspecific symptoms (e.g.,
fatigue, edema) to heart failure is often particularly challenging in this
patient population, because such symptoms can easily be mistakenly
attributed to noncardiac side effects of chemotherapy or to the
underlying malignancy itself. Hence, our findings that only one-third
of patients with asymptomatic left ventricular dysfunction received
therapy with angiotensin-converting enzyme inhibitors or beta-
blockers demonstrate substantial room for improvement.
We do not believe that the optimal screening/treatment prac-
tices for these patients are definitively clear. Thanks to the
groundbreaking work in Italy by Cardinale et al. (4,5), there is
strong (albeit single-center) evidence for a strategy of screening for
subclinical cardiotoxicity with troponin in patients treated with
high-dose chemotherapy or trastuzumab and in initiating
angiotensin-converting enzyme inhibitor therapy in the troponin-
positive cohort. The same group also demonstrated that therapy
with enalapril / carvedilol was more effective when instituted
arly in the setting of anthracycline-induced cardiomyopathy
6)—although, given that patients were not randomized in the
tudy, it is possible that patients with late-presentations were
self-selected” as individuals who by definition had not recovered
rom early acute injury without intervention. In the older cited
tudy by Tallaj et al. (7), the vast majority of patients had severe
ymptomatic heart failure, a population in whom treatment with
onventional heart failure therapy has a more definitively clear role.
In recent years, there has been tremendous growth of newancer therapies, many of which have off-target cardiac side effects
R1791JACC Vol. 57, No. 17, 2011 Correspondence
April 26, 2011:1787–91(e.g., trastuzumab, tyrosine kinase inhibitors). In many cases,
patients are cured of their malignancies and have a life expectancy
measured in decades—making optimal screening for and treatment
of cardiotoxicity a particularly critical issue. We are hopeful that
the work being performed on both sides of the Atlantic will
continue to better define optimal care of these patients.
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